Linda L. Garland

Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

James W. Welsh, Ritsuko Komaki, Arya Amini et al. · Journal of Clinical Oncology · 2013 · 394 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Resveratrol Modulates Drug- and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study

H.‐H. Sherry Chow, Linda L. Garland, Chiu‐Hsieh Hsu et al. · Cancer Prevention Research · 2010 · 325 citations · Full text

Medicine, Pharmacology, Biochemical Pharmacology +16

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

Daniel D. Karp, Luis Paz‐Ares, Silvia Novello et al. · Journal of Clinical Oncology · 2009 · 262 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study

Linda L. Garland, Cathryn Rankin, David R. Gandara et al. · Journal of Clinical Oncology · 2007 · 222 citations · Full text

Medicine, Oncology, Pharmacology +17

Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial.

Mary E. Reid, Anna J. Duffield‐Lillico, Linda L. Garland et al. · PubMed · 2002 · 218 citations

Public Health, Nutrition, Nutritional Sciences +14